Xiangchen Meng

Dr. Xiangchen Meng


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
MNMengmeng Niu
Mengmeng Niu
HGHuan-Xin Guo
Huan-Xin Guo
JCJun-Wu Cai
Jun-Wu Cai
XMXiangchen Meng
Xiangchen Meng
This study was designed to explore the different intestinal barrier repair mechanisms of Bifidobacterium breve (B. breve) H4-2 and H9-3 with different exopolysaccharide (EPS) production in mice with colitis. The lipopolysaccharide (LPS)-induced IEC-6 cell inflammation model and dextran sulphate sodium (DSS)-induced mice colitis model were used. Histopathological changes, epithelial barrier integrity, short-chain fatty acid (SCFA) content, cytokine levels, NF-κB expression level, and intestinal flora were analyzed to evaluate the role of B. breve in alleviating colitis. Cell experiments indicated that both B. breve strains could regulate cytokine levels. In vivo experiments confirmed that oral administration of B. breve H4-2 and B. breve H9-3 significantly increased the expression of mucin, occludin, claudin-1, ZO-1, decreased the levels of IL-6, TNF-α, IL-1β and increased IL-10. Both strains of B. breve also inhibited the expression of the NF-κB signaling pathway. Moreover, B. breve H4-2 and H9-3 intervention significantly increased the levels of SCFAs, reduced the abundance of Proteobacteria and Bacteroidea, and increased the abundance of Muribaculaceae. These results demonstrate that EPS-producing B. breve strains H4-2 and H9-3 can regulate the physical, immune, and microbial barrier to repair the intestinal damage caused by DSS in mice. Of the two strains, H4-2 had a higher EPS output and was more effective at repair than H9-3. These results will provide insights useful for clinical applications and the development of probiotic products for the treatment of colitis.

26 October 2022 in Food & Function
Verified
Journal Article
Closed access
PDF file
SYShuo Yang
Shuo Yang
JSJiacui Shang
Jiacui Shang
LLLijun Liu
Lijun Liu
ZTZongxin Tang
Zongxin Tang
XMXiangchen Meng
Xiangchen Meng
B. bifidum H3-R2, P. freudenreichii B1 and C. butyricum C1-6 exert protective effects against DSS-induced UC in mice by modulating inflammatory factors, intestinal barrier, related signalling pathways, gut microbiome and SCFAs levels.

1 September 2020 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
JSJiacui Shang
Jiacui Shang
FWFeng Wan
Feng Wan
LZLe Zhao
Le Zhao
XMXiangchen Meng
Xiangchen Meng
BLBailiang Li
Bailiang Li
The microbiota is directly involved in the development and modulation of the intestinal immune system. In particular, members of the genus Bifidobacterium play a primary role in immune regulation. In the present study, Bifidobacterium bifidum H3-R2 was screened from 15 bifidobacterium strains by in vitro experiment, showing a positive tolerance to digestive tract conditions, adhesion ability to intestinal epithelial cells and a regulatory effect on immune cell activity. Immunostimulatory activity of B. bifidum H3-R2 was also elucidated in vivo in cytoxan (CTX)-treated mice. The results showed that the administration of B. bifidum H3-R2 ameliorated the CTX-induced bodyweight loss and imbalanced expression of inflammatory cytokines, enhanced the production of secretory immunoglobulin A (SIgA), and promoted splenic lymphocyte proliferation, natural killer (NK) cell activity and phagocytosis of macrophages in immunosuppressed mice. In addition, B. bifidum H3-R2 restored injured intestinal mucosal, and increased the villus length and crypt depth in CTX-treated mice. The results could be helpful for understanding the functions of B. bifidum H3-R2, supporting its potential as a novel probiotic for immunoregulation.

21 November 2024 in Gut Microbes
Verified
Journal Article
Open access
SYShuo Yang
Shuo Yang
JCJunwu Cai
Junwu Cai
QSQian Su
Qian Su
QLQiaohui Li
Qiaohui Li
XMXiangchen Meng
Xiangchen Meng
Human milk oligosaccharides (HMOs) are the third most important nutrient in human milk and are the gold standard for infant nutrition. Due to the lack of an enzyme system capable of utilizing HMOs in the infant intestine, HMOs cannot be directly utilized. Instead, they function as natural prebiotics, participating in the establishment of the intestinal microbiota as a "bifidus factor." A crucial colonizer of the early intestine is Bifidobacterium longum (B. longum), particularly its subspecies B. longum subsp. infantis, which is the most active consumer of HMOs. However, due to the structural diversity of HMOs and the specificity of B. longum strains, studies on their synergy are limited. An in-depth investigation into the mechanisms of HMO utilization by B. longum is essential for applying both as synbiotics to promote early intestinal development in infants. This review describes the colonization advantages of B. longum in the infant intestinal tract and its metabolic strategies for HMOs. It also summarizes recent studies on the effect and mechanism of B. longum and HMOs in infant intestinal development directly or indirectly through the action of metabolites. In conclusion, further structural analysis of HMOs and a deeper understanding of the interactions between B. longum and HMOs, as well as clinical trials, are necessary to lay the foundation for future practical applications as synbiotics.

5 May 2025 in Food Research International
Verified
Journal Article
Closed access
SCSiyuan Chen
Siyuan Chen
YLYan Li
Yan Li
HYHang Yu
Hang Yu
PZPenghao Zhao
Penghao Zhao
XMXiangchen Meng
Xiangchen Meng
WWWeining Wang
Weining Wang

17 December 2025 in Food Chemistry
Verified
Journal Article
Closed access
WRWei Ruan
Wei Ruan
JLJiayu Liu
Jiayu Liu
HGHuanxin Guo
Huanxin Guo
SYShuo Yang
Shuo Yang
MNMengmeng Niu
Mengmeng Niu
XMXiangchen Meng
Xiangchen Meng